5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
19 citations
,
July 1997 in “British Journal of Dermatology” LHTric-1 is a specific antibody useful for studying hair and nail formation.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
4 citations
,
January 2019 in “Einstein (São Paulo)” Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
1 citations
,
November 2025 in “Journal of the American Academy of Dermatology”
May 2022 in “Gastroenterology” Targeting NETs may help reduce fibrosis in Crohn's disease.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
September 2015 in “Journal watch” Triamcinolone acetonide injections help regrow hair in alopecia areata patients.
October 2023 in “Indian journal of ophthalmology. Case reports” A woman lost vision in one eye after a forehead injection, but prompt treatment led to partial vision recovery.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
June 2025 in “Indus journal of bioscience research.” Combining microneedling with triamcinolone acetonide is more effective for treating alopecia areata than microneedling alone.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
13 citations
,
January 2018 in “International Journal of Trichology” Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
17 citations
,
January 2015 in “Dermatology online journal” A patient's grey hair regained color during treatment with adalimumab.
3 citations
,
September 2020 Dyclonine can effectively reduce skin issues by inhibiting the TRPV3 channel.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
1 citations
,
September 2024 in “Dermatological Reviews” Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.
April 2021 in “Journal of Investigative Dermatology” 2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.